Filter by: patients
Home > Community Treatment Reports and Side Effects > Epilepsy Phase 3 Study Retigabine IR Treatment Report
What is Epilepsy Phase 3 Study Retigabine IR?

NCT01227902 is an open-label, flexible dose study of retigabine immediate release (IR) as adjunctive therapy to specified monotherapy antiepileptic treatments in adults with partial-onset seizures. Other study IDs include: 113905 and IR.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
Epilepsy 1 1 Efficacy_major

See 1 patient currently using Epilepsy Phase 3 Study Retigabine IR

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
 0
Moderate
 0
Mild
 0
None
 1

Reported Schedules

  900 mg daily
  1 Number of Patients: 1  

Reported Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Adherence of Epilepsy Phase 3 Study Retigabine IR

Always
 1 100%
Usually
 0 0%
Sometimes
 0 0%
Never
 0 0%

Burden

Difficulty being on treatment

Burden of Epilepsy Phase 3 Study Retigabine IR

Very
 0 0%
Somewhat
 0 0%
A little
 0 0%
Not at all
 1 100%

Cost

Paid out of pocket

Cost of Epilepsy Phase 3 Study Retigabine IR

$200+
 0 0%
$100-199
 0 0%
$50-99
 0 0%
$25-49
 0 0%
< $25
 1 100%

Report created on May 26, 2012.